Literature DB >> 32041505

Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis.

J M Mejia-Vilet1, Y J López-Hernández1, J I Santander-Vélez1, M Trujeque-Matos1, C Cruz1, C A Carranza de la Torre1, V Espinosa-Cruz2, R Espinosa-González3, N O Uribe-Uribe3, L E Morales-Buenrostro1.   

Abstract

Angiotensin II type 1 receptor agonist antibodies (AT1R-AAs) have been associated with hypertension, atherosclerosis and vascular inflammation in human diseases. The aim of the study was to evaluate the prevalence of AT1R-AAs in active lupus nephritis (LN) patients and their association with vascular damage. One hundred and seven active LN patients underwent a complete clinical examination, measurement of AT1R-AAs, ambulatory blood pressure monitoring, carotid intima-media thickness measurement and morphometric analysis of subintimal fibrosis and medial hyperplasia of the vessels in the kidney tissue. Plasma AT1R-AAs were positive in 58 (54.2%) patients. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, complement C3 and C4 levels and titers of anti-dsDNA antibodies were higher in the group with positive AT1R-AAs compared with those with negative AT1R-AAs. The AT1R-AA titers correlated with anti-dsDNA antibody titers and with complement C3 and C4 serum levels. In the kidney biopsy, the percentage of subintimal fibrosis and the area of medial hyperplasia were greater in the AT1R-AA-positive patients. No differences in arterial pressure, carotid intima-media thickness and response to therapy were detected. In conclusion, AT1R-AAs are prevalent in active LN patients and are associated with histologic features of microvascular damage.

Entities:  

Keywords:  Angiotensin receptor antibody; angiotensin II receptor; anti-endothelial antibodies; lupus nephritis

Mesh:

Substances:

Year:  2020        PMID: 32041505     DOI: 10.1177/0961203320904787

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

2.  Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers.

Authors:  Khuraijam Dhanachandra Singh; Zaira P Jara; Terri Harford; Prasenjit Prasad Saha; Triveni R Pardhi; Russell Desnoyer; Sadashiva S Karnik
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-17       Impact factor: 11.205

3.  Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus.

Authors:  Daniel M McClung; William J Kalusche; Katie E Jones; Michael J Ryan; Erin B Taylor
Journal:  Physiol Rep       Date:  2021-02

Review 4.  Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.

Authors:  Jose L Labandeira-Garcia; Carmen M Labandeira; Rita Valenzuela; Maria A Pedrosa; Aloia Quijano; Ana I Rodriguez-Perez
Journal:  Biomedicines       Date:  2022-02-21

Review 5.  Non-HLA Antibodies in Kidney Transplantation: Immunity and Genetic Insights.

Authors:  Bogdan Marian Sorohan; Cătălin Baston; Dorina Tacu; Cristina Bucșa; Corina Țincu; Paula Vizireanu; Ioanel Sinescu; Ileana Constantinescu
Journal:  Biomedicines       Date:  2022-06-25

6.  Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients.

Authors:  Maciej Szymczak; Harald Heidecke; Marcelina Żabińska; Dagna Rukasz; Krzysztof Wiśnicki; Andrzej Tukiendorf; Magdalena Krajewska; Mirosław Banasik
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-09-24       Impact factor: 3.831

7.  Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19.

Authors:  Ana I Rodriguez-Perez; Carmen M Labandeira; Maria A Pedrosa; Rita Valenzuela; Juan A Suarez-Quintanilla; María Cortes-Ayaso; Placido Mayán-Conesa; Jose L Labandeira-Garcia
Journal:  J Autoimmun       Date:  2021-06-11       Impact factor: 7.094

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.